Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer

Inclusion Criteria: * Histologically confirmed hepatic colorectal metastasis by percutaneous hepatic biopsy * Imaging evidence of liver metastasis by CT helical scan * Resectable disease, as determined by a surgeon with hepatic surgery expertise (at least 10 resections performed per year) * Resectable, defined as a sparing of 2 adjacent liver segments with adequate vascular inflow and outflow and hepatic remnant volume * Minor resections (less than a hemihepatectomy) or major resections (hemihepatectomy or extended hepatectomy) allowed * Bilobar resection allowed, including atypical resections * No evidence of extrahepatic disease by chest x-ray or CT scan of the chest, abdomen, and pelvis * Performance status - Zubrod 0-1 * WBC at least 3,000/mm\^3 * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * Hemoglobin at least 9.0 g/dL * Bilirubin no greater than 2 mg/dL * AST and ALT no greater than 300 IU/L * No preexisting chronic hepatic disease (e.g., chronic active hepatitis or cirrhosis) that would preclude surgical resection of metastases * Creatinine no greater than 1.5 mg/dL * Creatinine clearance 60 mL/min * No symptomatic congestive heart failure * No unstable angina pectoris * No cardiac arrhythmia * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No other malignancy within the past 5 years except completely resected nonmelanoma skin cancer or carcinoma in situ of the cervix * No preexisting grade 2 or greater peripheral neuropathy * No concurrent uncontrolled illness * No ongoing or active infection * No psychiatric illness or social situation that would preclude study compliance * No concurrent biologic therapy * No concurrent sargramostim (GM-CSF) * More than 6 months since prior adjuvant fluorouracil-based chemotherapy * No prior chemotherapy for liver metastasis * No prior oxaliplatin for colorectal cancer * No prior or concurrent hepatic artery infusion chemotherapy for metastatic disease * No prior or concurrent radiotherapy for metastatic disease * No prior or concurrent radiofrequency ablation for metastatic disease * No prior or concurrent cryotherapy/other ablative techniques for metastatic disease * No other concurrent investigational therapy * No concurrent oral anticoagulation